BIND Therapeutics falls in 1st day on NasdaqSeptember 20, 2013 @ 3:07 pm
NEW YORK (AP) - Shares of drug developer BIND Therapeutics fell in its first day of trading on the Nasdaq.
The stock dropped 91 cents, or 6.1 percent, to close at $14.09 Friday after raising $70.5 million in an initial public offering of stock.
BIND Therapeutics Inc. priced the offering of 4.7 million shares at $15 each, in the middle of the expected range.
BIND Therapeutics has no products on the market. Its most advanced treatment candidate, BIND-014, is in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer. The company plans to use the offering's proceeds in part to fund BIND-014 development.
The Cambridge, Mass., company trades under the "BIND" ticker symbol.
(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Seattle's beleaguered tunnel project earns a spot atop a list of 11 'highway boondoggles'
'No War on Cars'
New head of Seattle DOT on controversies, congestion & the battle between bikes and cars
10 people you can't escape at Oktoberfest
Please login below with your Facebook, Twitter, Google+ or Disqus account. Existing MyNorthwest account holders will need to create a new Disqus account or use one of the social logins provided below. Thank you.